Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Cyanidin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 3/20 | 0.97 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.69 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.69 |
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.97 |
| ▸ | SNCA | P37840 | 3/20 | 0.97 |
| ▸ | CD38 | P28907 | 11/20 | 0.94 |
| ▸ | F2 | P00734 | 2/20 | 0.94 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.94 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.94 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.74 |
| ▸ | EP300 | Q09472 | 2/20 | 0.69 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyanidin SCHEMBL156277 | 0.98 | GLO1 (1.00) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL29547214 | 0.98 | GLO1 (1.00) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL7931530 | 0.97 | GLO1 (0.97) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL29414396 | 0.97 | CD38 (1.00) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL20799 | 0.97 | CD38 (1.00) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL29742342 | 0.95 | CD38 (0.97) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL30423220 | 0.95 | CD38 (0.97) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL608392 | 0.95 | CD38 (0.97) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL1644900 | 0.95 | CD38 (0.97) | GLO1SNCADPP4CD38F2 | |
| Cyanidin SCHEMBL6042006 | 0.94 | GLO1 (0.91) | GLO1SNCADPP4CD38F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| EP-3782649-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2021-02-24 | — | — | EP | disclosed |
| EP-2741779-A1 | HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS | Ascendis Pharma A/S (DK) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013160340-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013024048-A1 | POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024049-A1 | PROTEIN CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024047-A1 | HIGH-LOADING WATER-SOLUBLE CARRIER-LINKED PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| US-20130035635-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | ASCENDIS PHARMA A/S (DK) | 2013-02-07 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011089214-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035635-A1 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS | CTSL, SLC16A7, SLC16A8 | DPP4 110/4885EGFR 1635/4885KDR 843/4885 |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | DPP4 1529/4885EGFR 819/4885KDR 143/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | DPP4 1529/4885EGFR 819/4885KDR 143/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | DPP4 828/4885EGFR 2467/4885KDR 2030/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | DPP4 1529/4885EGFR 819/4885KDR 143/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | DPP4 828/4885EGFR 2467/4885KDR 2030/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | DPP4 334/4885EGFR 3398/4885KDR 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.